

# **Screening Libraries**

**Proteins** 

# **Product** Data Sheet

## TAT-p16

Cat. No.: HY-P10324

Molecular Formula:  $\mathsf{C}_{159}\mathsf{H}_{274}\mathsf{N}_{64}\mathsf{O}_{40}$ 

Molecular Weight: 3722.28

Sequence: Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Gly-Asp-Ala-Ala-Arg-Glu-Gly-Phe-Leu-Ala-Arg-Gly-Arg-Glu-Gly-Phe-Leu-Ala-Arg-Gly-Arg-Glu-Gly-Phe-Leu-Ala-Arg-Gly-Arg-Glu-Gly-Phe-Leu-Ala-Arg-Gly-Arg-Glu-Gly-Phe-Leu-Ala-Arg-Gly-Phe-Leu-Arg-Gly-Phe-

-Thr-Leu-Val-Val-Leu-His-Arg-Ala-Gly-Ala-Arg

Sequence Shortening: YGRKKRRQRRRGDAAREGFLATLVVLHRAGAR

Others Target: Others Pathway:

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

### **BIOLOGICAL ACTIVITY**

Description	TAT-p16 (p16INK4a peptide) is a peptide mimic of p16INK4a that can induce an early $G^{[1]}$ phase cell cycle arrest in the absence of active cyclin E:Cdk2 complex <sup>[1]</sup> .
In Vitro	TAT-p16 (10-100 $\mu$ M; 30 h) leads to a significant G <sub>1</sub> phase cell cycle arrest in human HaCaT keratinocytes <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Gius DR, et al. Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. Cancer Res. 1999 Jun 1;59(11):2577-80.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1